The inequality in the U.S. renal subsection is awkwardly rendered. Verify the named severity category in the label. eviQ provides a separate indexed-eGFR instruction for its metastatic breast cancer regimen.
Before applying: Consult the exact cited section and other applicable sources before use.
Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist
Choose a source to read (4)
Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.
eviQ protocol 3379, oral ribociclib for metastatic breast cancer.
Renal measure
Indexed eGFR in mL/min/1.73 m2.
Source revision
Kidney modification updated October 8, 2025; protocol change log includes October 30, 2026.
Retrieved
2026-11-07 (not the revision date)
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Protocol 3379, Dose modifications, Kidney dosing recommendations and treatment schedule
In its metastatic breast cancer protocol, eviQ retains the regimen at indexed eGFR 30 or above. Below 30 it advises a cautious 200 mg starting dose on treatment days because evidence is limited. Retain the protocol cycle and its ECG, electrolyte and blood-count monitoring.
Source revision: Kidney modification updated October 8, 2025; protocol change log includes October 30, 2026. | Retrieved: 2026-11-07. Retrieval date is not the revision date.
All sources, comparison tools and evidence navigation
Source-first renal review
Evidence sources and renal implications
Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.
Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.
Find:
Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.
All source summaries, original wording and provenance
Before applying a renal protocol
Check the setting. Compare whole sources.
No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.
Share a reproducible source review
Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.
Select two distinct source versions. The complete stored summaries will appear below.
Source-by-source comparison
These protocols may disagree and may apply to different settings. This view does not reconcile or endorse a patient-specific regimen.
Build a source-review outline for documentation
This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.
Choose one or two sources above or use the source checkboxes below.
Renal-context checklist: population, kidney trend and dialysis
These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.
Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.
These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.
Source scope / renal recommendation differences
Kisqali - product and source limitations
The inequality in the U.S. renal subsection is awkwardly rendered. Verify the named severity category in the label. eviQ provides a separate indexed-eGFR instruction for its metastatic breast cancer regimen.
How to use this: The inequality in the U.S. renal subsection is awkwardly rendered. Verify the named severity category in the label. eviQ provides a separate indexed-eGFR instruction for its metastatic breast cancer regimen.
Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.
Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.
Official source
Ribociclib tablets (Kisqali) - selected U.S. label sections
KISQALI oral tablets for breast cancer; not a combined letrozole package instruction.
Method: eGFR in mL/min/1.73 m2; severe category as specified by the label.
No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.
Compare or copy source versions
All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
U.S. product labeling / DailyMed · KISQALI oral tablets for breast cancer; not a combined letrozole package instruction.
Renal method: eGFR in mL/min/1.73 m2; severe category as specified by the label. Source date: Revision not captured; retrieval date is not the revision date. Retrieved: 2026-09-05
Local label summary; independent clinical review pending. Not a two-source validated protocol.
Renal dose comments
Mild or moderate renal impairment does not require adjustment. For severe impairment, the recommended starting dose is 200 mg once daily. Preserve the treatment cycle of 21 days on treatment followed by 7 days off, rather than converting this into continuous daily therapy.
RDM32-ribociclib-kisqali-1 · Source locator: 2.1; 2.2, Severe Renal Impairment; 8.7
Scope and monitoring
The concomitant endocrine therapy, toxicity modifications, ECG and electrolyte monitoring remain separate requirements. This summary does not assign a hemodialysis regimen.
Selected renal sections only, not a complete monograph. Exact product, indication, patient population, renal method and all other contraindications/interactions remain controlling.
Second independent renal reference and clinician adjudication remain pending; no all-indication, dialysis or pediatric dose may be inferred from an omitted field.
Renal guidance: 2, dosage modification for severe renal impairment; 8.7
For severe renal impairment, start at 200 mg once daily on the prescribed treatment days. Mild or moderate impairment does not require renal adjustment. Retain the indication-specific treatment cycle, ECG and electrolyte monitoring. Do not interpret a daily dose as continuous 28-day administration.
RDM73-kisqali-official-1 · Source locator: Renal guidance: 2, dosage modification for severe renal impairment; 8.7
GlobalRPh RX List / product-label mirror · Ribociclib (Kisqali), oral tablets for adult breast cancer
Renal method: Use the renal measure explicitly present in the RX passage. Source date: Mirror revision not established in the reviewed passage. Retrieved: 2026-11-07
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Protocol 3379, Dose modifications, Kidney dosing recommendations and treatment schedule
In its metastatic breast cancer protocol, eviQ retains the regimen at indexed eGFR 30 or above. Below 30 it advises a cautious 200 mg starting dose on treatment days because evidence is limited. Retain the protocol cycle and its ECG, electrolyte and blood-count monitoring.
Additional summaries stored on this page: 2 official-label, 1 RX List, 1 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.
This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.
